459 related articles for article (PubMed ID: 30077631)
61. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
[TBL] [Abstract][Full Text] [Related]
62. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma.
Arantes HP; Barros ER; Kunii I; Bilezikian JP; Lazaretti-Castro M
J Bone Miner Res; 2011 Dec; 26(12):2823-6. PubMed ID: 21997141
[TBL] [Abstract][Full Text] [Related]
63. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
[TBL] [Abstract][Full Text] [Related]
64. Clinical Course of Bone Metabolism Disorders in Patients with Inflammatory Bowel Disease: A 5-Year Prospective Study.
Casals-Seoane F; Chaparro M; Maté J; Gisbert JP
Inflamm Bowel Dis; 2016 Aug; 22(8):1929-36. PubMed ID: 27135482
[TBL] [Abstract][Full Text] [Related]
65. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
[TBL] [Abstract][Full Text] [Related]
66. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
67. Osteogenesis imperfecta in adults: phenotypic characteristics and response to treatment in an Irish cohort.
O'Sullivan ES; van der Kamp S; Kilbane M; McKenna M
Ir J Med Sci; 2014 Jun; 183(2):225-30. PubMed ID: 23918528
[TBL] [Abstract][Full Text] [Related]
68. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
69. Impact of alendronate on quality of life in children with osteogenesis imperfecta.
Seikaly MG; Kopanati S; Salhab N; Waber P; Patterson D; Browne R; Herring JA
J Pediatr Orthop; 2005; 25(6):786-91. PubMed ID: 16294137
[TBL] [Abstract][Full Text] [Related]
70. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
71. Management of atypical femoral fracture in a patient with osteogenesis imperfecta.
Tan JY; Seow CJ
BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29269360
[TBL] [Abstract][Full Text] [Related]
72. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
73. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
Zacharin M; Lim A; Gryllakis J; Siafarikas A; Jefferies C; Briody J; Heather N; Pitkin J; Emmanuel J; Lee KJ; Wang X; Simm PJ; Munns CF
J Clin Endocrinol Metab; 2021 Jul; 106(8):2328-2342. PubMed ID: 33954789
[TBL] [Abstract][Full Text] [Related]
74. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.
Kondo H; Okimoto N; Yoshioka T; Akahoshi S; Fuse Y; Ogawa T; Okazaki Y; Katae Y; Tsukamoto M; Yamanaka Y; Kawasaki M; Sakai A
J Bone Miner Metab; 2020 Nov; 38(6):894-902. PubMed ID: 32656645
[TBL] [Abstract][Full Text] [Related]
75. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
Jiang Y; Tang H; Ma X; Cheng Q; Lin H; Jin X; Zhang Z; Yu W; He S; Kobayashi T; Uehara S; Matsumoto T; Xia W
J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
[TBL] [Abstract][Full Text] [Related]
76. Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial.
Grey A; Horne A; Gamble G; Mihov B; Reid IR; Bolland M
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 32016386
[TBL] [Abstract][Full Text] [Related]
77. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements.
Nagant de Deuxchaisnes C; Devogelaer JP; Depresseux G; Malghem J; Maldague B
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S5-26. PubMed ID: 2187327
[TBL] [Abstract][Full Text] [Related]
78. Mineral bone disorder and osteoporosis in hemodialysis patients.
Slouma M; Sahli H; Bahlous A; Laadhar L; Smaoui W; Rekik S; Gharsallah I; Sallami M; Moussa FB; Elleuch M; Cheour E
Adv Rheumatol; 2020 Feb; 60(1):15. PubMed ID: 32102689
[TBL] [Abstract][Full Text] [Related]
79. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
80. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]